Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.


Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada
Bayer announces agreements to resolve major legacy Monsanto litigation
Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer
Bayer partners with Population Health Research Institute (PHRI) on major global research study on COVID-19 treatments
Bayer Scholarships for Students Now Accepting Applications for 2020
ALTAIR study published confirming efficacy of EYLEA® treat and extend dosing regimens for patients with wet AMD
New treatment for men with non-metastatic castration resistant prostate cancer approved in Canada
Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer